<i>p16</i> promoter methylation is a potential predictor of malignant transformation in oral epithelial dysplasia



Hall, Gillian L, Shaw, Richard J ORCID: 0000-0001-7027-8997, Field, E Anne, Rogers, Simon N, Sutton, David N, Woolgar, Julia A, Lowe, Derek, Liloglou, Triantafillos ORCID: 0000-0003-0460-1404, Field, John K ORCID: 0000-0003-3951-6365 and Risk, Janet M ORCID: 0000-0002-8770-7783
(2008) <i>p16</i> promoter methylation is a potential predictor of malignant transformation in oral epithelial dysplasia. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 17 (8). pp. 2174-2179.

[img] Microsoft Word
Risk_-_p16_methylation_predicts_malignancy_CEBP_final.doc - Author Accepted Manuscript

Download (206kB)
[img] PDF
739.pdf - Author Accepted Manuscript

Download (135kB)

Abstract

Management of the patient with oral epithelial dysplasia depends on the ability to predict malignant transformation. Histologic grading of this condition fails in this regard and is also subject to interpathologist and intrapathologist variability. This study uses longitudinal clinical samples to explore the prognostic value of a previously validated panel of methylation biomarkers in a cohort of patients with histologically proven oral dysplasia. Methylation enrichment pyrosequencing assays were used to provide the sensitivity of traditional methylation-specific PCR with the additional specificity advantages of a subsequent confirmatory sequencing reaction. In 57% (8 of 14) patients with a lesion that transformed to oral squamous cell carcinoma, 26% (26 of 100) of longitudinal samples collected over > or =3 years showed p16 methylation. Only 1% (2 of 184) of samples from 8% of patients (2 of 24) not undergoing malignant transformation within 3 years had p16 methylation. Both of these samples with p16 promoter methylation were the most recently collected and the patients remain under continuing clinical review. Promoter methylation of MGMT, CYGB, and CCNA1 did not correlate with malignant progression. We thus conclude that methylation of the p16 gene promoter shows promise as a predictor for malignant transformation (Fisher's exact, P = 0.002) in a subset of patients.

Item Type: Article
Additional Information: Hall, Gillian L Shaw, Richard J Field, E Anne Rogers, Simon N Sutton, David N Woolgar, Julia A Lowe, Derek Liloglou, Triantafillos Field, John K Risk, Janet M Research Support, Non-U.S. Gov't United States Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2174-9.## TULIP Type: Articles/Papers (Journal) ##
Uncontrolled Keywords: Humans, Mouth Neoplasms, Cell Transformation, Neoplastic, Biopsy, Statistics, Nonparametric, Prospective Studies, Predictive Value of Tests, Polymerase Chain Reaction, DNA Methylation, Female, Male, Cyclin-Dependent Kinase Inhibitor p16, Promoter Regions, Genetic, Biomarkers, Tumor
Subjects: ?? RK ??
Divisions: Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences > School of Dentistry
Depositing User: Symplectic Admin
Date Deposited: 10 Jun 2008 08:25
Last Modified: 17 Oct 2023 02:05
DOI: 10.1158/1055-9965.EPI-07-2867
Publisher's Statement : © 2008 American Association for Cancer Research
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/739